Group
|
ALT (U/l)
|
AST (U/l)
|
ALP (U/l)
|
LDH (U/l)
|
---|
Control
|
44.63 ± 0.49 b
|
72.83 ± 0.12b
|
120.7 ± 0.33 b
|
70.50 ± 1.04b
|
CP
|
138.3 ± 0.29a
|
192.4 ± 0.35a
|
350.0 ± 0.58 a
|
92.83 ± 0.60a
|
AHE alone
|
44.57 ± 0.23b
|
72.63 ± 0.19 b
|
120.9 ± 0.21b
|
70.33 ± 0.67b
|
CP + AHE
|
101.8 ± 0.28a, b, d
|
140.4 ± 0.30 a, b, d
|
299.2 ± 0.42a, b, d
|
84.67 ± 0.67a, b, d
|
AHE + CP
|
46.60 ± 0.31a, b, c
|
75.97 ± 0.55a, b, c
|
135.8 ± 0.28a, b, c
|
76.30 ± 0.35a, b, c
|
CP + Sily
|
47.17 ± 0.17a**, b
|
75.53 ± 0.53 a, b
|
134.0 ± 0.55a, b
|
73.50 ± 0.50b
|
- Values expressed as mean ± SEM
-
a Significance at p < 0.0001 Vs. control group
-
b Significance at p < 0.0001 Vs. Cisplatin (CP) group
-
c Significance at p < 0.0001 of AHE + CP pre-treated group Vs. CP + AHE post-treated group
-
d Significance at p < 0.0001 of CP + AHE treatment groups Vs CP + Sily group
-
** Significant difference at p < 0.001. Non-significant difference (p > 0.05) was recorded between control and AHE alone treated group in all parameters (One way ANOVA followed by Tukey’s multiple comparison tests)